The stock exchange announced that Diamond Biotechnology (6901) will start public subscription of shares today (7th), and the processing period will be until September 11th, and the lottery will begin on September 13th. The underwriting price per share is 40 yuan. If converted to the opening price of 63.2 yuan on September 6, a lucky winner is expected to earn 23,000 yuan in cash, sparking discussion.
What exactly is this company “Diamond Biotech” doing and what’s so great about it? The following is a report from July 2022:
"Ten years of hard work, biotechnology is Taiwan's next economic lifeline." Lu Kongming, chairman of Taiwan's sustainable biotechnology venture capital Diamond Biotech, said firmly. Diamond Biotechnology indonesia telegram is one of the few companies in Taiwan that can truly invest in and mentor early-stage biotechnology startups. It has finally entered the capital market in its tenth year since its establishment. It is expected to be listed on the stock market on the 25th with a reference price of 35 yuan per share and will apply for listing next year.
The first sustainable venture capital to support flagship biotech
On the 21st, Diamond Biotech held a pre-launch Dharma talk, and the venue was crowded with people. This is the first "sustainable biotech venture capital" to be registered in the listing since the Financial Supervisory Commission approved the listing of large-scale sustainable venture capital in February 2016.
Different from the general venture capital investment period which has a business period of 7 to 10 years, Diamond Biotechnology was positioned as a sustainable venture capital company when it was established in 2013. It is interested in the long technology research and development cycle, high risks and long-term investment in the biotechnology industry. Period support.
- Board index
- All times are UTC
- Delete cookies
- Contact us